Nisa Investment Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,076
| Closed | -$102K | – | 3137 |
|
|
2026
Q1 | $102K | Hold |
5,076
| – | – | ﹤0.01% | 1416 |
|
|
2025
Q4 | $82K | Buy |
5,076
+519
| +11% | +$6.87K | ﹤0.01% | 1492 |
|
|
2025
Q3 | $55.5K | Hold |
4,557
| – | – | ﹤0.01% | 1600 |
|
|
2025
Q2 | $51.5K | Hold |
4,557
| – | – | ﹤0.01% | 1582 |
|
|
2025
Q1 | $52.6K | Buy |
4,557
+218
| +5% | +$2.23K | ﹤0.01% | 1578 |
|
|
2024
Q4 | $36.8K | Sell |
4,339
-26
| -0.6% | -$269 | ﹤0.01% | 1767 |
|
|
2024
Q3 | $50.5K | Sell |
4,365
-15
| -0.3% | -$189 | ﹤0.01% | 1643 |
|
|
2024
Q2 | $51.6K | Buy |
4,380
+29
| +0.7% | +$338 | ﹤0.01% | 1658 |
|
|
2024
Q1 | $51.6K | Buy |
4,351
+12
| +0.3% | +$160 | ﹤0.01% | 1648 |
|
|
2023
Q4 | $53.2K | Hold |
4,339
| – | – | ﹤0.01% | 1622 |
|
|
2023
Q3 | $41.8K | Hold |
4,339
| – | – | ﹤0.01% | 1777 |
|
|
2023
Q2 | $39.1K | Buy |
4,339
+1,240
| +40% | +$11.4K | ﹤0.01% | 1834 |
|
|
2023
Q1 | $24K | Hold |
3,099
| – | – | ﹤0.01% | 1955 |
|
|
2022
Q4 | $21K | Buy |
+3,099
| New | +$16.6K | ﹤0.01% | 2046 |
|
|
2021
Q3 | – | Sell |
-2,400
| Closed | -$58K | – | 2315 |
|
|
2021
Q2 | $58K | Buy |
+2,400
| New | +$62.8K | ﹤0.01% | 1894 |
|
Other funds holding KALV
Nisa Investment Advisors's KALV Position: Q2 2026 in Review
Nisa Investment Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 5,076 shares — an estimated $102K sold.
Nisa Investment Advisors first reported a position in KALV in Q2 2021 and held it in 15 quarters. The position peaked at $102K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Nisa Investment Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Nisa Investment Advisors sold 5,076 KalVista Pharmaceuticals shares in Q2 2026, an estimated $102K.
- Nisa Investment Advisors first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 15 quarters.
- Nisa Investment Advisors's KalVista Pharmaceuticals position peaked at $102K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.